Uterine cancer treatment and diagnostics abroad

Uterine cancer is a broad term for malignancies arising in the body of the womb. The most common form is endometrial cancer, which starts in the uterine lining. Uterine sarcoma is rarer and develops in muscle or supporting tissues; its assessment and treatment differ. Cancer beginning in the cervix is a separate diagnosis. Abnormal vaginal bleeding, particularly bleeding after menopause, needs medical assessment, although many non-cancerous conditions can cause similar symptoms.

Diagnosis relies on appropriate examination and tissue assessment, with imaging used when needed to investigate the problem or its extent. A specialist team considers the exact tumour type, stage, relevant molecular findings, general health and personal priorities before recommending care. Treatment may involve surgery, radiotherapy or drug therapy in different combinations. Bring biopsy reports and previous scans to a consultation, and discuss fertility, possible treatment effects and follow-up. A page description cannot determine an individual's diagnosis or likely outcome.

Understanding the exact diagnosis

Endometrial cancer and uterine sarcoma are different diseases. A pathology report identifies the tumour type and helps direct care. For endometrial cancer, grade and molecular features can add information beyond tumour size. Sarcoma subtypes require a separate assessment; a treatment plan should not be copied from another uterine cancer diagnosis.

Symptoms and diagnostic assessment

Bleeding after menopause, unusual bleeding between periods or a change in vaginal discharge should be checked. These symptoms do not prove cancer, but assessment should not be postponed while arranging a consultation abroad. Tell the clinician about previous hormone treatment, medicines and any family history of cancer.

Tests may include transvaginal ultrasound, endometrial sampling and hysteroscopy, depending on the clinical question. Tissue examination confirms endometrial cancer. Discuss pain management and preparation for a proposed biopsy. Once cancer is identified, additional imaging such as MRI or CT may help assess its extent; not every test is necessary for every patient.

How treatment decisions are made

A multidisciplinary oncology team combines the pathology, staging information and general health assessment. Surgery is often important for endometrial cancer, but the operation and any lymph node assessment are selected individually. Radiotherapy may be recommended after surgery or in other circumstances. Chemotherapy, hormone treatment, targeted treatment or immunotherapy may be appropriate for selected disease settings.

Molecular testing can influence risk assessment and systemic treatment decisions. Uterine sarcoma needs a plan matched to its subtype and extent. Neither a stage label nor a new technology alone provides a reliable personal prognosis. Ask what each proposed treatment aims to achieve and how its benefits compare with the possible harms.

Life after treatment

Discuss effects on fertility, menopause symptoms, sexual health and recovery before treatment starts. Ask who will coordinate follow-up and which new symptoms should be reported between appointments. Take copies of pathology, operation notes and treatment summaries when care involves several teams.

Frequently asked questions

Is uterine cancer the same as cervical cancer?

No. They start in different areas and have different assessment and treatment pathways.

Can a cervical smear exclude uterine cancer?

No. Cervical screening does not reliably screen for endometrial cancer. Abnormal bleeding still needs assessment.

Will everyone need the same operation?

No. The tumour type, extent, health and treatment goals determine which procedures are appropriate.

Can fertility be preserved?

Only selected situations may allow a fertility-preserving approach. Discuss eligibility and specialist monitoring before treatment; it is not suitable for every uterine cancer.